The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Redox Biology

Volumn 13, Issue , 2017, Pages 370-385

  Steven, Sebastian ^a   Oelze, Matthias ^a   Hanf, Alina ^a   Kröller Schön, Swenja ^a   Kashani, Fatemeh ^a   Roohani, Siyer ^a   Welschof, Philipp ^a   Kopp, Maximilian ^a   Gödtel Armbrust, Ute ^a   Xia, Ning ^a   Li, Huige ^a,d   Schulz, Eberhard ^a   Lackner, Karl J ^b   Wojnowski, Leszek ^a   Bottari, Serge P ^c   Wenzel, Philip ^a,d   Mayoux, Eric ^d   Münzel, Thomas ^a,d   Daiber, Andreas ^a,d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIV GRENOBLE ALPES   (France)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

AGE RAGE signaling; Diabetes; Endothelial dysfunction; Low grade inflammation; Oxidative stress; SGLT2 inhibitor; Zucker diabetic fatty rats; cell content

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; EMPAGLIFLOZIN; FPSZM 1; HEMOGLOBIN A1C; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; GLUCOSE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SGLT2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR MORTALITY; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC COMPLICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EPIGENETICS; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPERLIPIDEMIA; INFLAMMATION; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PLEIOTROPY; PRECLINICAL STUDY; PRIORITY JOURNAL; RAT; RESPIRATORY BURST; SIGNAL TRANSDUCTION; THORACIC AORTA; ZUCKER DIABETIC FATTY RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETIC CARDIOMYOPATHY; DRUG EFFECTS; METABOLISM; VASCULAR ENDOTHELIUM; ZUCKER RAT;

ANIMALS; AORTA, THORACIC; BENZHYDRYL COMPOUNDS; C-REACTIVE PROTEIN; DIABETIC CARDIOMYOPATHIES; ENDOTHELIUM, VASCULAR; GLUCOSE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; OXIDATIVE STRESS; RATS; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85021409196     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.06.009     Document Type: Article

References (84)

1. Nathan, D.M., Cleary, P.A., Backlund, J.Y., Genuth, S.M., Lachin, J.M., Orchard, T.J., Raskin, P., Zinman, B., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353 (2005), 2643–2653.
2. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., E.-R. O. investigators, empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 (2015), 2117–2128.
3. Jay, D., Hitomi, H., Griendling, K.K., Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40 (2006), 183–192.
4. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M., Thaiss, F., Stahl, R.A., Warnholtz, A., Meinertz, T., Griendling, K., Harrison, D.G., Forstermann, U., Munzel, T., Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88 (2001), E14–E22.
5. Zou, M.H., Shi, C., Cohen, R.A., Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Investig. 109 (2002), 817–826.
6. Alp, N.J., Mussa, S., Khoo, J., Cai, S., Guzik, T., Jefferson, A., Goh, N., Rockett, K.A., Channon, K.M., Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Investig. 112 (2003), 725–735.
7. Heitzer, T., Krohn, K., Albers, S., Meinertz, T., Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43 (2000), 1435–1438.
8. Cassuto, J., Dou, H., Czikora, I., Szabo, A., Patel, V.S., Kamath, V., Belin de Chantemele, E., Feher, A., Romero, M.J., Bagi, Z., Peroxynitrite disrupts endothelial caveolae leading to eNOS uncoupling and diminished flow-mediated dilation in coronary arterioles of diabetic patients. Diabetes 63 (2014), 1381–1393.
9. Forbes, J.M., Cooper, M.E., Thallas, V., Burns, W.C., Thomas, M.C., Brammar, G.C., Lee, F., Grant, S.L., Burrell, L.A., Jerums, G., Osicka, T.M., Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 (2002), 3274–3282.
10. Yamamoto, Y., Yamagishi, S., Yonekura, H., Doi, T., Tsuji, H., Kato, I., Takasawa, S., Okamoto, H., Abedin, J., Tanaka, N., Sakurai, S., Migita, H., Unoki, H., Wang, H., Zenda, T., Wu, P.S., Segawa, Y., Higashide, T., Kawasaki, K., Yamamoto, H., Roles of the age-RAGE system in vascular injury in diabetes. Ann. N. Y Acad. Sci., 902(163–170), 2000 (discussion170-162).
11. Coughlan, M.T., Thorburn, D.R., Penfold, S.A., Laskowski, A., Harcourt, B.E., Sourris, K.C., Tan, A.L., Fukami, K., Thallas-Bonke, V., Nawroth, P.P., Brownlee, M., Bierhaus, A., Cooper, M.E., Forbes, J.M., RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 20 (2009), 742–752.
12. Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M., Wautier, J.L., Activation of NADPH oxidase by age links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280 (2001), E685–E694.
13. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I., Brownlee, M., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000), 787–790.
14. Schulz, E., Wenzel, P., Munzel, T., Daiber, A., Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal 20 (2014), 308–324.
15. Kroller-Schon, S., Steven, S., Kossmann, S., Scholz, A., Daub, S., Oelze, M., Xia, N., Hausding, M., Mikhed, Y., Zinssius, E., Mader, M., Stamm, P., Treiber, N., Scharffetter-Kochanek, K., Li, H., Schulz, E., Wenzel, P., Munzel, T., Daiber, A., Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid. Redox Signal 20 (2014), 247–266.
16. Bucciarelli, L.G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L.L., Goova, M.T., Moser, B., Kislinger, T., Lee, D.C., Kashyap, Y., Stern, D.M., Schmidt, A.M., RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002), 2827–2835.
17. Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D.R., Thomson, S.C., Koepsell, H., Vallon, V., Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia, American journal of physiology., Am. J. Physiol. Renal Physiol.306, 2014, F188–F193.
18. Oelze, M., Kroller-Schon, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinssius, E., Agdauletova, S., Gottschlich, A., Steven, S., Schulz, E., Bottari, S.P., Mayoux, E., Munzel, T., Daiber, A., The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One, 9, 2014, e112394.
19. Scheen, A.J., Paquot, N., Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab. 40 (2014), S4–S11.
20. Evans, J.L., Goldfine, I.D., Aging and insulin resistance: just say iNOS. Diabetes 62 (2013), 346–348.
21. Fala, L., Jardiance (empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2. Diabetes, Am. Health Drug Benefits 8 (2015), 92–95.
22. Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., E.-R. O. t. investigators, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur. Heart J. 37 (2016), 1526–1534.
23. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., Maggioni, A.P., McMurray, J.J., Probstfield, J.L., Riddle, M.C., Solomon, S.D., Tardif, J.C., E. Investigators, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med 373 (2015), 2247–2257.
24. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., Josse, R., Kaufman, K.D., Koglin, J., Korn, S., Lachin, J.M., McGuire, D.K., Pencina, M.J., Standl, E., Stein, P.P., Suryawanshi, S., Van de Werf, F., Peterson, E.D., Holman, R.R., Group, T.S., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med 373 (2015), 232–242.
25. Hansen, H.H., Jelsing, J., Hansen, C.F., Hansen, G., Vrang, N., Mark, M., Klein, T., Mayoux, E., The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J. Pharmacol. Exp. Ther. 350 (2014), 657–664.
26. Vickers, S.P., Cheetham, S.C., Headland, K.R., Dickinson, K., Grempler, R., Mayoux, E., Mark, M., Klein, T., Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes, Metab. Syndr. Obes.: Targets Ther. 7 (2014), 265–275.
27. Cheng, S.T., Chen, L., Li, S.Y., Mayoux, E., Leung, P.S., The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes. PLoS One, 11, 2016, e0147391.
28. Oelze, M., Kröller-Schön, S., Mader, M., Zinßius, E., Stamm, P., Hausding, M., Mayoux, E., Wenzel, P., Schulz, E., Münzel, T., Daiber, A., Effects of empagliflozin on oxidative stress and endothelial dysfunction in STZ-induced Type 1 diabetic rat. Diabetol. Stoffwechs., 9, 2014, P247.
29. Wenzel, P., Schulz, E., Oelze, M., Muller, J., Schuhmacher, S., Alhamdani, M.S., Debrezion, J., Hortmann, M., Reifenberg, K., Fleming, I., Munzel, T., Daiber, A., AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic. Biol. Med. 45 (2008), 619–626.
30. Kroller-Schon, S., Knorr, M., Hausding, M., Oelze, M., Schuff, A., Schell, R., Sudowe, S., Scholz, A., Daub, S., Karbach, S., Kossmann, S., Gori, T., Wenzel, P., Schulz, E., Grabbe, S., Klein, T., Munzel, T., Daiber, A., Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 96 (2012), 140–149.
31. Oelze, M., Daiber, A., Brandes, R.P., Hortmann, M., Wenzel, P., Hink, U., Schulz, E., Mollnau, H., von Sandersleben, A., Kleschyov, A.L., Mulsch, A., Li, H., Forstermann, U., Munzel, T., Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48 (2006), 677–684.
32. Oelze, M., Knorr, M., Schuhmacher, S., Heeren, T., Otto, C., Schulz, E., Reifenberg, K., Wenzel, P., Munzel, T., Daiber, A., Vascular dysfunction in streptozotocin-induced experimental diabetes strictly depends on insulin deficiency. J. Vasc. Res. 48 (2011), 275–284.
33. Oelze, M., Kroller-Schon, S., Steven, S., Lubos, E., Doppler, C., Hausding, M., Tobias, S., Brochhausen, C., Li, H., Torzewski, M., Wenzel, P., Bachschmid, M., Lackner, K.J., Schulz, E., Munzel, T., Daiber, A., Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension 63 (2014), 390–396.
34. McMichael, M., Hellstrom-Lindahl, E., Weiner, H., Identification and selective precipitation of human aldehyde dehydrogenase isozymes using antibodies raised to horse liver aldehyde dehydrogenase isozymes. Alcohol., Clin. Exp. Res. 10 (1986), 323–329.
35. Hausding, M., Jurk, K., Daub, S., Kroller-Schon, S., Stein, J., Schwenk, M., Oelze, M., Mikhed, Y., Kerahrodi, J.G., Kossmann, S., Jansen, T., Schulz, E., Wenzel, P., Reske-Kunz, A.B., Becker, C., Munzel, T., Grabbe, S., Daiber, A., CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Res Cardiol., 108, 2013, 386.
36. Umlauf, D., Goto, Y., Feil, R., Site-specific analysis of histone methylation and acetylation. Methods Mol. Biol. 287 (2004), 99–120.
37. Cosseau, C., Grunau, C., Native chromatin immunoprecipitation. Methods Mol. Biol. 791 (2011), 195–212.
38. Wu, Z., Siuda, D., Xia, N., Reifenberg, G., Daiber, A., Munzel, T., Forstermann, U., Li, H., Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring. Hypertension 65 (2015), 232–237.
39. Li, H., Junk, P., Huwiler, A., Burkhardt, C., Wallerath, T., Pfeilschifter, J., Forstermann, U., Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 106 (2002), 2250–2256.
40. Lin, M.I., Fulton, D., Babbitt, R., Fleming, I., Busse, R., Pritchard, K.A. Jr, Sessa, W.C., Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J. Biol. Chem. 278 (2003), 44719–44726.
41. Fleming, I., Fisslthaler, B., Dimmeler, S., Kemp, B.E., Busse, R., Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 88 (2001), E68–E75.
42. Chen, L., Klein, T., Leung, P.S., Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr. Mol. Med. 12 (2012), 995–1004.
43. Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C.S., Nishii, N., Yamada, H., Takei, K., Makino, H., Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9, 2014, e100777.
44. Tokuyama, Y., Sturis, J., DePaoli, A.M., Takeda, J., Stoffel, M., Tang, J., Sun, X., Polonsky, K.S., Bell, G.I., Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44 (1995), 1447–1457.
45. Prentki, M., Nolan, C.J., Islet beta cell failure in type 2 diabetes. J. Clin. Investig. 116 (2006), 1802–1812.
46. Kuriyama, C., Xu, J.Z., Lee, S.P., Qi, J., Kimata, H., Kakimoto, T., Nakayama, K., Watanabe, Y., Taniuchi, N., Hikida, K., Matsushita, Y., Arakawa, K., Saito, A., Ueta, K., Shiotani, M., Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats. J. Pharmacol. Exp. Ther. 351 (2014), 423–431.
47. Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., Conway, J., Polidori, D., Ways, K., Demarest, K., Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One, 7, 2012, e30555.
48. Watanabe, Y., Nakayama, K., Taniuchi, N., Horai, Y., Kuriyama, C., Ueta, K., Arakawa, K., Senbonmatsu, T., Shiotani, M., Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. PLoS One, 10, 2015, e0116851.
49. Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., Kim-Mitsuyama, S., Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc. Diabetol., 13, 2014, 148.
50. Luippold, G., Klein, T., Mark, M., Grempler, R., Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes, Obes. Metab. 14 (2012), 601–607.
51. Perkins, B.A., Cherney, D.Z., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N.M., Kaspers, S., Woerle, H.J., Broedl, U.C., Johansen, O.E., Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37 (2014), 1480–1483.
52. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., Woerle, H.J., von Eynatten, M., Broedl, U.C., The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol., 13, 2014, 28.
53. Bierhaus, A., Fleming, T., Stoyanov, S., Leffler, A., Babes, A., Neacsu, C., Sauer, S.K., Eberhardt, M., Schnolzer, M., Lasitschka, F., Neuhuber, W.L., Kichko, T.I., Konrade, I., Elvert, R., Mier, W., Pirags, V., Lukic, I.K., Morcos, M., Dehmer, T., Rabbani, N., Thornalley, P.J., Edelstein, D., Nau, C., Forbes, J., Humpert, P.M., Schwaninger, M., Ziegler, D., Stern, D.M., Cooper, M.E., Haberkorn, U., Brownlee, M., Reeh, P.W., Nawroth, P.P., Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med 18 (2012), 926–933.
54. Sun, M., Yokoyama, M., Ishiwata, T., Asano, G., Deposition of advanced glycation end products (age) and expression of the receptor for age in cardiovascular tissue of the diabetic rat. Int. J. Exp. Pathol. 79 (1998), 207–222.
55. Wautier, J.L., Wautier, M.P., Schmidt, A.M., Anderson, G.M., Hori, O., Zoukourian, C., Capron, L., Chappey, O., Yan, S.D., Brett, J., et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA 91 (1994), 7742–7746.
56. Daiber, A., Steven, S., Weber, A., Shuvaev, V.V., Muzykantov, V.R., Laher, I., Li, H., Lamas, S., Munzel, T., Targeting vascular (endothelial) dysfunction. Br. J. Pharmacol. 174 (2017), 1591–1619.
57. Daiber, A., Di Lisa, F., Oelze, M., Kroller-Schon, S., Steven, S., Schulz, E., Munzel, T., Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br. J. Pharmacol. 174 (2017), 1670–1689.
58. Tekabe, Y., Anthony, T., Li, Q., Ray, R., Rai, V., Zhang, G., Schmidt, A.M., Johnson, L.L., Treatment effect with anti-RAGE F(ab’)2 antibody improves hind limb angiogenesis and blood flow in Type 1 diabetic mice with left femoral artery ligation. Vasc. Med. 20 (2015), 212–218.
59. Grauballe, M.B., Ostergaard, J.A., Schou, S., Flyvbjerg, A., Holmstrup, P., Blockade of RAGE in Zucker obese rats with experimental periodontitis. J. Periodontal Res., 2016.
60. Vallon, V., Gerasimova, M., Rose, M.A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S.C., Rieg, T., SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice, American journal of physiology. Ren. Physiol. 306 (2014), F194–F204.
61. Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V.T., Hohenstein, B., Hugo, C., The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am. J. physiol. Ren. Physiol. 307 (2014), F317–F325.
62. Bassirat, M., Khalil, Z., Short- and long-term modulation of microvascular responses in streptozotocin-induced diabetic rats by glycosylated products. J. Diabetes Complicat. 24 (2010), 64–72.
63. Han, J.H., Oh, T.J., Lee, G., Maeng, H.J., Lee, D.H., Kim, K.M., Choi, S.H., Jang, H.C., Lee, H.S., Park, K.S., Kim, Y.B., Lim, S., The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia, 2016.
64. Thomas, L., Tadayyon, M., Mark, M., Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)−8-(3-amino-piperidin-1-yl)−7-but-2-ynyl-3-methyl-1-(4-methyl-quinazol in-2-ylmethyl)−3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J. Pharmacol. Exp. Ther. 328 (2009), 556–563.
65. Ferreira, L., Teixeira-de-Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R., Garrido, P., Sereno, J., Fernandes, R., Santos, P., Velada, I., Melo, A., Nunes, S., Teixeira, F., Reis, F., Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediat. Inflamm., 2010, 2010, 592760.
66. Apaijai, N., Pintana, H., Chattipakorn, S.C., Chattipakorn, N., Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. Br. J. Pharmacol. 169 (2013), 1048–1057.
67. Yokoi, N., Hoshino, M., Hidaka, S., Yoshida, E., Beppu, M., Hoshikawa, R., Sudo, K., Kawada, A., Takagi, S., Seino, S., A novel rat model of type 2 diabetes: the Zucker fatty diabetes mellitus ZFDM rat. J. Diabetes Res., 2013, 2013, 103731.
68. Bolinder, J., Ljunggren, O., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A.M., Sugg, J., Parikh, S., Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97 (2012), 1020–1031.
69. Chen, Z., Zhang, J., Stamler, J.S., Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad. Sci. USA 99 (2002), 8306–8311.
70. Sydow, K., Daiber, A., Oelze, M., Chen, Z., August, M., Wendt, M., Ullrich, V., Mulsch, A., Schulz, E., Keaney, J.F. Jr., Stamler, J.S., Munzel, T., Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J. Clin. Investig. 113 (2004), 482–489.
71. Wenzel, P., Hink, U., Oelze, M., Schuppan, S., Schaeuble, K., Schildknecht, S., Ho, K.K., Weiner, H., Bachschmid, M., Munzel, T., Daiber, A., Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J. Biol. Chem. 282 (2007), 792–799.
72. Chen, C.H., Budas, G.R., Churchill, E.N., Disatnik, M.H., Hurley, T.D., Mochly-Rosen, D., Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321 (2008), 1493–1495.
73. Wang, J., Wang, H., Hao, P., Xue, L., Wei, S., Zhang, Y., Chen, Y., Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol. Med. 17 (2011), 172–179.
74. Wenzel, P., Schuhmacher, S., Kienhofer, J., Muller, J., Hortmann, M., Oelze, M., Schulz, E., Treiber, N., Kawamoto, T., Scharffetter-Kochanek, K., Munzel, T., Burkle, A., Bachschmid, M.M., Daiber, A., Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc. Res. 80 (2008), 280–289.
75. Brandt, M., Garlapati, V., Oelze, M., Sotiriou, E., Knorr, M., Kroller-Schon, S., Kossmann, S., Schonfelder, T., Morawietz, H., Schulz, E., Schultheiss, H.P., Daiber, A., Munzel, T., Wenzel, P., NOX2 amplifies acetaldehyde-mediated cardiomyocyte mitochondrial dysfunction in alcoholic cardiomyopathy. Sci. Rep., 6, 2016, 32554.
76. Wenzel, P., Muller, J., Zurmeyer, S., Schuhmacher, S., Schulz, E., Oelze, M., Pautz, A., Kawamoto, T., Wojnowski, L., Kleinert, H., Munzel, T., Daiber, A., ALDH-2 deficiency increases cardiovascular oxidative stress–evidence for indirect antioxidative properties. Biochem Biophys. Res. Commun. 367 (2008), 137–143.
77. Wolkart, G., Beretta, M., Wenzl, M.V., Stessel, H., Schmidt, K., Maeda, N., Mayer, B., Schrammel, A., Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency. Br. J. Pharmacol. 168 (2013), 1868–1877.
78. Srinivasan, K., Ramarao, P., Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 125 (2007), 451–472.
79. Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., Yamagishi, S., Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm. Metab. Res. 47 (2015), 686–692.
80. Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., Woerle, H.J., Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes, Obes. Metab. 15 (2013), 613–621.
81. Hawley, S.A., Ford, R.J., Smith, B.K., Gowans, G.J., Mancini, S.J., Pitt, R.D., Day, E.A., Salt, I.P., Steinberg, G.R., Hardie, D.G., The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65 (2016), 2784–2794.
82. Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thevenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W.J., Sener, A., Deprez, B., Abderrahmani, A., Staels, B., Pattou, F., Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21 (2015), 512–517.
83. Jufvas, A., Sjodin, S., Lundqvist, K., Amin, R., Vener, A.V., Stralfors, P., Global differences in specific histone H3 methylation are associated with overweight and type 2 diabetes. Clin. Epigenetics, 5, 2013, 15.
84. Miao, F., Smith, D.D., Zhang, L., Min, A., Feng, W., Natarajan, R., Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 57 (2008), 3189–3198.